#6/II.D.S.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 10/088,569

10/088,569

APPLICANT Robert C. Brunham

FILING DATE August 13, 2002

GROUP
August 13, 2002

Sheet \_1 of 3

ATTY. DOCKET NO. 10/088,569

FILING DATE August 13, 2002

SERIAL NO. 10/088,569

FILING DATE August 13, 2002

## **U.S. PATENT DOCUMENTS**

*INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL	FILING DATE
	5,589,466	Dec. 31, 1998	Felgner et al	514	44	
					()()	

## **FOREIGN PATENT DOCUMENTS**

<del></del>	DOCUMENT NO.	DATE	COUNTRY	CLAS S	SUBC L.	TRANS	LATION
	0192033	Aug. 27,1986	Europe			YES	NO
	WO 98/02546 A	Jan. 22, 1998	PCT				
	40-46 (1995) 2. D. M. Pardoll 3, 165-169 ( 3. W.M. McDor (1996) 4. J. B. Ulmer e a viral protein 5. B. Wang et a immunodefic	and A. M. Beckerie 1995) anell and F. K. Aska et al., Heterologous n. Vol. 259, 1745-17 al., Gene inoculation iency virus type 1.	cy of intramuscular g, Exposing the imr ri, Molecular Medic protection against in '49 (1993) n generates immun /ol. 90, 4156-4160	immunizat munology ine. DNA v nfluenza b e respons (1993)	of naked D vaccines. V y injection es against	ONA vaccir /ol. 334, 4 of DNA en	nes.Vol. 2-45 ncoding
	with plasmid 7. E. Raz et al., induction of c 8. Z. Q. Xiang e	et al., Bovine Herpi DNA. Vol. 67, 5664 Intradermal gene in ellular immunity to v t al., Vaccination wi protective immunity	-5667(1993) nmunization: the po viruses. Vol. 91, 951 th a plasmid vector	ssible role 9-9523 (1 carrying th	of DNA up 994). ne rabies v	ptake in th	e

DEC 1 7 2002

15 Mar	DEC 1 7 20
1 6 Mar (E)	2 TECH CENTED 161
" Trans	9. J.J. Donnelly et al., Protection against papillomavirus with a polynucleotide vaccine. Vol. 511, 160 713, 314-320 (1996)
No TRACE	10. D. L. Montgomery et al., Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of DNA vectors. Vol.12, 777-783 (1993)
	11. J.J. Donnelly et al., Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus. Vol. 1, 583-587 (1995).
	12. G. H. Rhodes et al., Characterization of humoral immunity after DNA injection. Vol. 82, 229-236 (1994).
	13. H. L. Davis, M. L. Michel, R. G. Whalen, DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Vol.2, 1847 –1851 (1993)
	14. J. B. Ulmer. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vol. 12, 154 1-1544 (1994).
	15. Z. Xiang and H. C. J. Ertl. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Vol. 2, 129-135 (1995)
	16. E. F. Fynan et al, DNA vaccines: Protective immunization by parenteral, mucosal, and gene-gun inoculations.Vol. 90, pages. 11478-11482 (1993)
	17. E. Manickan, et al., Genetic immunization against herpes simplex virus. Vol. 155, 259-265 (1995)
	18. M. Sedegah et al , Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Vol. 91, pp. 9866-9870 (1994)
	19. M.A. Barry, et al., Protection against mycoplasma infection using expression-library immunization. Vol. 377, 632-635 (1995)
	20. D. Xu and F. Y. Liew, Genetic vaccination against leishmaniasis. Vol. 12, 1534-1536 (1994)
	21. D. B. Lowrie, et al., Towards and DNA vaccine against tuberculosis. Vol. 12, 1537-1540 (1994)
	22. J. W. Moulder, et al., Interaction of chlamydiae and host cells in vitro. Vol. 55, 143-190 (1991)
	23. J. Schachter, The intracellular life of chlamydia. Vol. 138, 109-139 (1988)
	24. S. D. Hillis and J. N. Wasserheit, Screening for chlamydia-a key to the prevention of pelvic inflammatory disease. Vol. 334, 1399-1401 (1996)
	<ol> <li>R. C. Brunham and R. W. Peeling, Chlamydia trachomatis antigens: Role in immunity and pathogenesis. Vol. 3, 218-233 (1994).</li> </ol>
	26. R. P. Morrison, D.S. Manning, H. D. Caldwell, Immunology of chlamydial trachomatis infections. 1992, pp. 57-84
	27. J. T. Grayston and S-P. Wang, The potential for vaccine against infection of the genital tract with chlamydia trachomatis. Vol. 5, 73-77 (1978)
	28. J.T. Grayston and SP Wang, New knowledge of chlamydia and the diseases they cause.  Vol. 132, 87-105 (1975)
	29. H. R. Taylor, et al. Oral immunization with chalmydia major oute rmembrane protein (MOMP) Vol. 29, 1847-1853 (1988)
	30. B.E. Batteiger, et al., Partial protection against genital reinfection by imunization of guinea pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitis. 139, pp. 2965-2972 (1993)
	31. M. Campos et al., A chlamydial major outer membrane protein extract as a trachoma vaccine candidate. Vol. 36, 1477-1491 (1995)
	32. H. Su, M. Parnell, et al., Protective efficacy of parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies fo not protect against chlamydial genital tract infection. Vol. 13, 1023-1032 (1995)
	33. T W. Tan, Protection of sheep against chlamydia psittaci infection with a subcellular vaccine containing the major outer membrane protein. Vol. 58, 3101-3108 (1990)
F	

1 - 40	3  34. M. Tuffrey, et al., Heterotypic protection of mice against chlamydial salpingitis and CENTER colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane	EIVE
· 📆	DEC	TIVE
1 6 2002 2		7 2002
· · · · · · · · · · · · · · · · · · ·	34. M. Tuffrey, et al., Heterotypic protection of mice against chlamydial salpingitis and CENTER	
MACE	colonization of the lower genital tract with a human serovar F isolate of Chlamydia	1600/20
& TRADEMA	trachomatis by prior immunization with recombinant serovar L1 major outer-membrane	10/20
	protein. 138, 1707-1715 (1992)	<u>}</u>
	35. Y X. Zhang, J. G. Fox, Y. Ho., Comparison of the major Outer-Membrane protein	l l
	(MOMP) gene of mouse pneumonitis (MoPn) and hamster SFPD strains of chlamydia	
	trachomatis with other Chlamydia strains.10(6), pages: 1327-1342 (1993)	}
	36. R. P. Morrison, et al., Gene knockout mice establish a primary protective role for major	
	histocompatibility complex class II-Restricted responses in chlamydia trachomatis genital	
	tract infection. Vol. 63, 4661-4668 (1995)  37. H. Su and H. D. Caldwell, CD4*T cell play a singnificant role in aadoptive immunity to	}
	chlamydia trachomatis infection of the mouse genital tract. Vol. 63, 3302-3308 (1995)	
	38. J. U. Igietseme et al., Resolution of murine chlamydial genital infection by the adoptive	1
	transfer of Biovar-Specific, TH1 Lymphocyte Clone. 5, 317–324 (1993)	}
	39. J. U. Igietseme, et al., Susceptibility to reinfection after a primary chlamydia genital	ll .
}	infection is associated with a decrease of antigen-specific T cells in the genital tract. Vol.	
	59, 1346-1351 (1991)	}
	40. D. M. Williams, et al., Cellular immunity to the mouse pneumonitis agent. Vol. 149, 630-	ŀ
	639 (1984)	
	41. G. Tipples and G. McClarty, Cloning and expression of the chlamydia trachomatis gene	i,
	for CTP synthetase. Vol. 270, 7908-7914 (1995).	
	42. X. Yang, K. et al., Genetically determined differences in IL-10 and IFN-v response correlate with clearance of chlanydia trachomatid mouse pneumonitis infection. Vol.156,	
1	4338-4344 (1996)	1
	43. Tang et al., Genetic immunization is a simple method for eliciting an immune response.	
	1992, Vol. 356, pp. 152-154	
	44. Davis et al., Direct gene transfer in skeletal muscle: plasmid DNA-based immunization	
	against the hepatitis B virus surface antigen. 1994, Vol. 12: 1503-1509.	
	45. Holzman L.B. et al., Identification, molecualr cloning, and characterization of dula leucine	
	zipper bearing kinase. 1994. Pages. 30808-30817. XP-002120730	
1	46. Stephens, R.S. et al., Genome sequence of an obligate intracellular pathogen of humnas:	
	Chlamydia trachomatis. Vol. 282 (1998) pages. 759-759 XP-002104802	
	47. Green et al, "Liposomal Vaccines", Adv. Exp. Med. Biol. 383:83-92	
	48. Baxby et al, "Potential use of nonreplicating vectors as recombinant vaccines", Vaccine,	
	10(1): 8-9	
	49. Anderson et al, "Immune response in mice following immunization with DNA encoding	1
	fragment C of tetanus toxin, Inf. Immun. 64(8): 3168-3173	1
	50. Kaul et al, "Expression of the Chlamydia trachomatis major outer membrane protein-	
	encoding gene in Escherichia coli: role of the 3' end in mRNA stability," Gene 87(1):97-104	
	51. Douglas et al, "Mutagenesis of the P2 promoter of the major outer membrane protein	
	gene of Chlamydia trachomatis", J. Bacteriol., 178(19):5573-5578	
	52. Dascher et al, "Expression and translocation of the chlamydial major outer membrane protein in Escherichia coli", Microbial Pathogenesis, 15: 455-467	
<del></del>	53. M.A. LIU, M.R. Hilleman, R.Kurth, Overview of DNA Vaccines Ann. N.Y. Acad. Sci. 772	
	(1995) pages 15-20	
XAMINER:		
		li .

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.